Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV
Journal
International Journal of Antimicrobial Agents
Journal Volume
58
Journal Issue
3
Pages
106403
Date Issued
2021
Author(s)
Lee Y.-L.
Cheng S.-H.
Lu P.-L.
Wang N.-C.
Ho M.-W.
Yang C.-J.
Liou B.-H.
Tang H.-J.
Huang S.-S.
Huang S.-H.
Chen T.-C.
Lin C.-Y.
Lin S.-P.
Lee Y.-T.
Taiwan HIV Study Group
Abstract
Real-world experience with dolutegravir (DTG) plus boosted protease inhibitor (bPI) as a two-drug regimen is limited for highly experienced HIV-positive patients with virological failure or intolerance to antiretroviral therapy. Patients receiving DTG plu
SDGs
Other Subjects
dolutegravir; proteinase inhibitor; antiretrovirus agent; dipyrone; fused heterocyclic rings; integrase inhibitor; oxazine derivative; piperazine derivative; adult; antiretroviral therapy; antiviral resistance; Article; body weight gain; combination drug
Publisher
Elsevier B.V.
Type
journal article